Brightseed Raises $68 Million To Pioneer AI In Bioactives Discovery
Brightseed, a company with goals in discovering bioactive plant components for the better health of humanity, has raised $68 million through a Series B funding round led by Temasek Holdings.
Created on May 10|Last edited on May 10
Comment
Brightseed is a company with a dedication to human health through nutrition. Bioactives are certain molecular compounds with profound effects, such as caffeine, and are even used in medicine. Though we consume these every day, research put into discovering the details of new, potentially important, bioactives is lacking in terms of speed and scalability.
Forager is Brightseed's key technology, helping them push the field of discovering novel bioactives forward at a rapid pace. Powered by deep learning AI, Forager is a digital platform tailor made for predicting which plant compounts are bioactive, and how they could potentially impact certain areas of human health.
We’re excited to announce our $68 million in Series B funding led by Temasek with participation from all existing and new investors who support our mission of illuminating nature to restore human health. https://t.co/WuKJ0Cajx5#artificialintelligence #health #plantscience
— Brightseed (@BrightseedBio) May 9, 2022
Who's funding Brightseed and where's the money going?
Brightseed raised $68 million in a Series B funding round lead by Temasek Holdings. Additional funding participation is thanks to AgFunder, Continental Grain Company, Germin8 Ventures, Lews & Clark AgriFood, and S2G Ventures.
Brightseed will be using these funds to further improve it's existing technology for bioactives discovery, hoping to discover valueable bioactives that could be added to food and beverage, as well as medicine, for a healthier future.
Find out more
Add a comment
Tags: ML News
Iterate on AI agents and models faster. Try Weights & Biases today.